Management of chemotherapy-induced nausea and vomiting

Acta Clinica Belgica

Volumn 65, Issue 5, 2010, Pages 305-310

  Van Ryckeghem, F ^a   Van Belle, S ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Anti emetic therapy; Chemotherapy; Prevention

Indexed keywords

ANTINEOPLASTIC AGENT; APREPITANT; BENZODIAZEPINE; CANNABINOID; CASOPITANT; CORTICOSTEROID; DEXAMETHASONE; FOSAPREPITANT; METHYLPREDNISOLONE; OLANZAPINE; PALONOSETRON;

ACNE; AGITATION; APPETITE; CANCER CHEMOTHERAPY; CANCER THERAPY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INDIGESTION; INSOMNIA; NAUSEA AND VOMITING; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; SIDE EFFECT; WEIGHT GAIN;

EID: 78149379297     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1179/acb.2010.067     Document Type: Review

References (33)

1. Coates A., Abraham S., Kaye SB. et al. On the receiving end - patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983; 19: 203-208.
2. Grunberg SM, Deuson RR, Mavros P. et al. Incidence of Chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 2004; 100: 2261-2268.
3. Schwartzberg L. Chemotherapy-induced nausea and vomiting: state of the art in 2006. J Support Oncol 2006; 4: 3-8. (Pubitemid 43338178)
4. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008; 358: 2482-2494.
5. Schnell FM. Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. Oncologist 2003; 8: 187-198. (Pubitemid 36428284)
6. Kris MG, Gralla RJ, Clark RA et al. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplalin. J Clin Oncol 1985; 10: 1379-1384.
7. Hesketh PJ, Van Belle S, Aapro M et al. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer 2003; 39: 1074-1080.
8. Geling O and Eichler H-G. Should 5 hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug costs implications. J Clin Oncol 2005; 23: 1289-1294.
9. Herstedt J, Koeller JM, Roila F et al. Acute emesis: moderately emetogenic chemotherapy. Support Care Cancer 2005; 13: 97-103.
10. Del Giglio A, Soares HP, Caparroz C and Castro PC. Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting. Cancer 2000; 89: 2301-2308.
11. Gralla R, Lichinitser M, Van der Vegt S et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Annal Oncol 2003; 14: 1570-1577. (Pubitemid 37304615)
12. Grunberg SM. Antiemetic activity in corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis. Ann Oncol 2007; 18: 233-240.
13. Vardy J, Chiew KS, Galica J, Pond GR and Tannock IF. Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 2006; 94: 1011-1015.
14. Bountra C, Bunce K, Dale T et al. Anti-emetic profile of a non-peptide neurokinin NK1 receptor antagonist, CP-99,994, in ferrets. Eur J Pharmacol 1993; 249: R3-4.
15. Kris MG, Radford JE, Pizzo BA, Inabinet R, Hesketh A and Hesketh PJ. Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin. J Natl Cancer Inst 1997; 89: 817-818. (Pubitemid 27242284)
16. Van Belle SJP and Cocquyt V. Fosaprepitant dimeglumine (MK-0517 or L-785,298), an intravenous neurokinin-1 antagonist for the prevention of chemotherapy induced nausea and vomiting. Expert Opin Pharmacother 2008; 9: 1-10.
17. Grunberg S, Aziz Z, Shaharyar A, et al. Phase III results of a novel oral neurokinin-1 (NK-1) receptor antagonist, casopitant: single oral and 3-day oral dosing regimens for chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving moderately emetogenic chemotherapy (MEC) [abstract 9540]. J Clin Oncol 2008; ASCO Annual Meeting Proceedings 26;
18. 1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from 2 randomised, double-blind, placebo controlled trials. Eur J Cancer 2005; 41: 1278-1285.
19. Warr DG, Hesketh PJ, Gralla RJ et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005; 23: 2822-2830.
20. Herstedt J, Muss HB, Warr DG et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately emetogenic chemotherapy. Cancer 2005; 104: 1548-1555. (Pubitemid 41356171)
21. Hesketh PJ, Grunberg SM, Gralla RJ et al. The oral neurokinin-1 receptor antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - The aprepitant protocol 052 study group. J Clin Oncol 2003; 21: 4112-4119.
22. Shadle CR, Lee Y, Majumdar AK et al. Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. J Clin Pharmacol 2004; 44: 215-223. (Pubitemid 38233818)
23. Dando TM and Perry CM. Aprepitant, a review of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 2004; 64: 777-794.
24. Grunberg SM, Rolski J, Strausz J et al. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 549-558.
25. Tramer MR, Carroll D, Campbell FA, Reynolds JM, Moore A and McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2001; 323: 1-8.
26. Navari RM, Einhorn LH, Loehrer PJ et al. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study. Support Care Cancer 2007; 15: 1285-1291.
27. Kris MG, Hesketh PJ, Somerfield MR et al. American society of clinical oncology guideline for antiemetics in oncology: Update 2006. J Clin Oncol 2006; 24: 2932-2947
28. Herrstedt J and Roila F. Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis. Annal Oncol 2009; 20: 156-158.
29. Available from : http://www.mascc.org/media/Resource-centers/MAS-CC- Guidelines-Update.pdf, last accessed 15-07-2009.
30. Drug Utilization Review Team (DURTO). Antiemetic prescriptions in Italian breast cancer patients submitted to adjuvant chemotherapy. Support Care Cancer 2003; 11: 785-789.
31. Kaiser R. Antiemetic guidelines: are they being used? Lancet Oncol 2005; 6: 622-625.
32. Van Belle S, Awada A, Dicato M et al. AVOID: Anti-emetics for Chemotherapy induced Nausea and Vomiting (CINV): a Retrospective Descriptive Study [abstract 3604] European CanCer Organisation 15-European Society for Medical Oncology Meeting Proceedings 15-34; 2009.
33. Navari RM. Antiemetic control: toward a new standard of care for emetogenic chemotherapy. Expert Opin Pharmacother 2009; 10: 629-644.